Logo image of ALEC

ALECTOR INC (ALEC) Stock Fundamental Analysis

NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD

1.67  +0.06 (+3.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALEC. ALEC was compared to 558 industry peers in the Biotechnology industry. ALEC may be in some trouble as it scores bad on both profitability and health. ALEC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALEC had negative earnings in the past year.
In the past year ALEC has reported a negative cash flow from operations.
ALEC had negative earnings in each of the past 5 years.
ALEC had negative operating cash flow in 4 of the past 5 years.
ALEC Yearly Net Income VS EBIT VS OCF VS FCFALEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

ALEC's Return On Assets of -30.23% is fine compared to the rest of the industry. ALEC outperforms 65.95% of its industry peers.
ALEC has a Return On Equity (-130.47%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.23%
ROE -130.47%
ROIC N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ALEC Yearly ROA, ROE, ROICALEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEC Yearly Profit, Operating, Gross MarginsALEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALEC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALEC has been increased compared to 5 years ago.
Compared to 1 year ago, ALEC has a worse debt to assets ratio.
ALEC Yearly Shares OutstandingALEC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALEC Yearly Total Debt VS Total AssetsALEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.86, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.86, ALEC perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
ALEC has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
ALEC has a worse Debt to Equity ratio (0.10) than 65.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -2.86
ROIC/WACCN/A
WACC9.63%
ALEC Yearly LT Debt VS Equity VS FCFALEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 3.34 indicates that ALEC has no problem at all paying its short term obligations.
The Current ratio of ALEC (3.34) is worse than 60.75% of its industry peers.
A Quick Ratio of 3.34 indicates that ALEC has no problem at all paying its short term obligations.
ALEC has a Quick ratio of 3.34. This is comparable to the rest of the industry: ALEC outperforms 40.68% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.34
ALEC Yearly Current Assets VS Current LiabilitesALEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

ALEC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.70%, which is quite good.
ALEC shows a decrease in Revenue. In the last year, the revenue decreased by -8.35%.
ALEC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.53% yearly.
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
Revenue 1Y (TTM)-8.35%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-76.88%

3.2 Future

ALEC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.94% yearly.
Based on estimates for the next years, ALEC will show a quite strong growth in Revenue. The Revenue will grow by 15.25% on average per year.
EPS Next Y-56.26%
EPS Next 2Y-15.67%
EPS Next 3Y5.33%
EPS Next 5Y9.94%
Revenue Next Year-80.72%
Revenue Next 2Y-10.03%
Revenue Next 3Y23.02%
Revenue Next 5Y15.25%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALEC Yearly Revenue VS EstimatesALEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ALEC Yearly EPS VS EstimatesALEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALEC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEC Price Earnings VS Forward Price EarningsALEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEC Per share dataALEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.67%
EPS Next 3Y5.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALEC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALECTOR INC

NASDAQ:ALEC (7/14/2025, 12:05:47 PM)

1.67

+0.06 (+3.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners80.75%
Inst Owner Change0%
Ins Owners6.13%
Ins Owner Change2.3%
Market Cap166.98M
Analysts77.14
Price Target5.18 (210.18%)
Short Float %7.07%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.02%
Min EPS beat(2)17.12%
Max EPS beat(2)96.92%
EPS beat(4)4
Avg EPS beat(4)39.19%
Min EPS beat(4)17.12%
Max EPS beat(4)96.92%
EPS beat(8)8
Avg EPS beat(8)43.05%
EPS beat(12)10
Avg EPS beat(12)38.69%
EPS beat(16)11
Avg EPS beat(16)-1.92%
Revenue beat(2)1
Avg Revenue beat(2)101.11%
Min Revenue beat(2)-17.7%
Max Revenue beat(2)219.92%
Revenue beat(4)2
Avg Revenue beat(4)50.19%
Min Revenue beat(4)-17.7%
Max Revenue beat(4)219.92%
Revenue beat(8)5
Avg Revenue beat(8)156.01%
Revenue beat(12)7
Avg Revenue beat(12)117.15%
Revenue beat(16)7
Avg Revenue beat(16)76.8%
PT rev (1m)0%
PT rev (3m)10.91%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)7.38%
EPS NY rev (1m)5.38%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)-3.51%
Revenue NQ rev (3m)-37.16%
Revenue NY rev (1m)17.53%
Revenue NY rev (3m)13.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.89
P/FCF N/A
P/OCF N/A
P/B 1.76
P/tB 1.76
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.29
OCFYN/A
SpS0.88
BVpS0.95
TBVpS0.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.23%
ROE -130.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.11%
ROA(5y)-21.34%
ROE(3y)-84.42%
ROE(5y)-67.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.34
Altman-Z -2.86
F-Score1
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)45.58%
Cap/Depr(5y)54.45%
Cap/Sales(3y)2.26%
Cap/Sales(5y)6.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
EPS Next Y-56.26%
EPS Next 2Y-15.67%
EPS Next 3Y5.33%
EPS Next 5Y9.94%
Revenue 1Y (TTM)-8.35%
Revenue growth 3Y-21.4%
Revenue growth 5Y36.53%
Sales Q2Q%-76.88%
Revenue Next Year-80.72%
Revenue Next 2Y-10.03%
Revenue Next 3Y23.02%
Revenue Next 5Y15.25%
EBIT growth 1Y1.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.33%
EBIT Next 3Y12.79%
EBIT Next 5Y9.46%
FCF growth 1Y-10.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.48%
OCF growth 3YN/A
OCF growth 5YN/A